| Peer-Reviewed

Hematological Malignancies: Epidemiological, Clinical, Biological, Therapeutic and Evolutionary Aspects

Received: 10 February 2019     Accepted: 12 March 2019     Published: 13 April 2019
Views:       Downloads:
Abstract

Hematological malignancies are diseases, which include all cancers of blood and lymphoid organs. They result from a proliferation of mature blood cells or immature blood cells. However, in all cases, these blood cells escape the normal regulation. This work aims to determine the types and frequencies of diagnosed malignancies. It’s supported by the clinical hematological department of the Military Hospital Avicenna in Marrakech. We conducted a retrospective study over a period of 4 years from January, 1st 2012 to December, 31st 2015. We used an operating record, which includes epidemiological, clinical, biological, therapeutic and evolutionary criteria. During this period, we found that 70 cases were diagnosed and treated in the clinical hematological department of the HMA. We recorded 26 cases of multiple myeloma (37%), 23 cases of leukemia (33%), 19 cases of lymphoma (including 15 cases of non-Hodgkin lymphoma (21.4%) and 4 cases of Hodgkin lymphoma 5.7 %), 1 case of myelodysplastic syndrome (1.4%) and 1 case of polycythemia vera (1.4%). This work allowed us to note a significant increase in malignancies in this study. Hence the importance of raising the awareness of health professionals and raising awareness on a larger scale of the general population to improve the time of care and indirectly improve the prognosis of these diseases.

Published in American Journal of Laboratory Medicine (Volume 4, Issue 1)
DOI 10.11648/j.ajlm.20190401.13
Page(s) 19-23
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2019. Published by Science Publishing Group

Keywords

Hematological Malignancies, Epidemiology, Biology

References
[1] Mahboub. F. Z, Elkhattabi. W, L’youssfi. H, Aichaneet. A, Afif. H. Diagnostic positif et évolution des hémopathies malignes (à propos de 132 cas). Rev Mal Respir 2015; 32: A130-A130.
[2] Delabesse E. Marqueurs génétiques des hémopathies. EMC- Biologiemédicale 2018; 13: 1-8.
[3] Thachil. J, Bates. I. Approach to the Diagnosis and Classification oh Blood Cell Disorders. Practical Haematology 2017; 23: 497-510.
[4] Questel. F. Hémopathies malignes d'origine professionnelle. Pathologie professionnelle et de l'environnement 2011; 6: 1-12.
[5] RHAFEL. A. Bilan d’activité du service d’hématologie du CHU Mohammed VI (2009-2013). Thèse de doctorat en médecine, sous la direction du Pr. L. Mahmal, Marrakech, Faculté de médecine et de pharmacie, 2014; 223: 42-43.
[6] Harif. M, Benider. A, BennaniOthmani. M. et al. Registre des cancers de la région du Grand Casablanca 2012; 88: 72-78.
[7] Troussard. X, Duchenet. V, Cornet. E, Mouchel. D, Malet. M, Collignon. A. Epidémiologie des hémopathies malignes en Basse-Normandie. ‎Rev. épidémiol. santé publique 2009; 57: 151-158.
[8] Fouquet. G, Guidez. S, Richez. V, Systchenko. T, Gruchet. C, Moya. N et all. Myélome multiple. EMC- Hématologie 2017; 12: 1-26.
[9] Arnulf. B. Myélome multiple des os. Rev Prat 2013; 63: 101–8.
[10] Laroche. M. Myélome multiple des os (maladie de Kahler). Rhumatologie pour le praticien 2018; 21: 257-263.
[11] Tazi. M, Benjaafar. N, er-raki. A. Incidences des cancers à Rabat 2005; 84: 82-82.
[12] Duployez. N, Decool. G, Preudhomme. C. Classification et facteurs pronostiques des leucémies aiguës. EMC- Hématologie 2018; 13: 1-14.
[13] Opsomer. M.-A, Fagnoni. P, Bastie Pr. J.-N. Lymphomes. Pharmacie clinique pratique en oncologie 2016; 26: 211-211.
Cite This Article
  • APA Style

    Mouhib Hanane, Zahir Hanane, Mouayche Ikhlas, Yahyaoui Hicham, Ait Ameur Mustapha, et al. (2019). Hematological Malignancies: Epidemiological, Clinical, Biological, Therapeutic and Evolutionary Aspects. American Journal of Laboratory Medicine, 4(1), 19-23. https://doi.org/10.11648/j.ajlm.20190401.13

    Copy | Download

    ACS Style

    Mouhib Hanane; Zahir Hanane; Mouayche Ikhlas; Yahyaoui Hicham; Ait Ameur Mustapha, et al. Hematological Malignancies: Epidemiological, Clinical, Biological, Therapeutic and Evolutionary Aspects. Am. J. Lab. Med. 2019, 4(1), 19-23. doi: 10.11648/j.ajlm.20190401.13

    Copy | Download

    AMA Style

    Mouhib Hanane, Zahir Hanane, Mouayche Ikhlas, Yahyaoui Hicham, Ait Ameur Mustapha, et al. Hematological Malignancies: Epidemiological, Clinical, Biological, Therapeutic and Evolutionary Aspects. Am J Lab Med. 2019;4(1):19-23. doi: 10.11648/j.ajlm.20190401.13

    Copy | Download

  • @article{10.11648/j.ajlm.20190401.13,
      author = {Mouhib Hanane and Zahir Hanane and Mouayche Ikhlas and Yahyaoui Hicham and Ait Ameur Mustapha and Chakour Mohammed},
      title = {Hematological Malignancies: Epidemiological, Clinical, Biological, Therapeutic and Evolutionary Aspects},
      journal = {American Journal of Laboratory Medicine},
      volume = {4},
      number = {1},
      pages = {19-23},
      doi = {10.11648/j.ajlm.20190401.13},
      url = {https://doi.org/10.11648/j.ajlm.20190401.13},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajlm.20190401.13},
      abstract = {Hematological malignancies are diseases, which include all cancers of blood and lymphoid organs. They result from a proliferation of mature blood cells or immature blood cells. However, in all cases, these blood cells escape the normal regulation. This work aims to determine the types and frequencies of diagnosed malignancies. It’s supported by the clinical hematological department of the Military Hospital Avicenna in Marrakech. We conducted a retrospective study over a period of 4 years from January, 1st 2012 to December, 31st 2015. We used an operating record, which includes epidemiological, clinical, biological, therapeutic and evolutionary criteria. During this period, we found that 70 cases were diagnosed and treated in the clinical hematological department of the HMA. We recorded 26 cases of multiple myeloma (37%), 23 cases of leukemia (33%), 19 cases of lymphoma (including 15 cases of non-Hodgkin lymphoma (21.4%) and 4 cases of Hodgkin lymphoma 5.7 %), 1 case of myelodysplastic syndrome (1.4%) and 1 case of polycythemia vera (1.4%). This work allowed us to note a significant increase in malignancies in this study. Hence the importance of raising the awareness of health professionals and raising awareness on a larger scale of the general population to improve the time of care and indirectly improve the prognosis of these diseases.},
     year = {2019}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Hematological Malignancies: Epidemiological, Clinical, Biological, Therapeutic and Evolutionary Aspects
    AU  - Mouhib Hanane
    AU  - Zahir Hanane
    AU  - Mouayche Ikhlas
    AU  - Yahyaoui Hicham
    AU  - Ait Ameur Mustapha
    AU  - Chakour Mohammed
    Y1  - 2019/04/13
    PY  - 2019
    N1  - https://doi.org/10.11648/j.ajlm.20190401.13
    DO  - 10.11648/j.ajlm.20190401.13
    T2  - American Journal of Laboratory Medicine
    JF  - American Journal of Laboratory Medicine
    JO  - American Journal of Laboratory Medicine
    SP  - 19
    EP  - 23
    PB  - Science Publishing Group
    SN  - 2575-386X
    UR  - https://doi.org/10.11648/j.ajlm.20190401.13
    AB  - Hematological malignancies are diseases, which include all cancers of blood and lymphoid organs. They result from a proliferation of mature blood cells or immature blood cells. However, in all cases, these blood cells escape the normal regulation. This work aims to determine the types and frequencies of diagnosed malignancies. It’s supported by the clinical hematological department of the Military Hospital Avicenna in Marrakech. We conducted a retrospective study over a period of 4 years from January, 1st 2012 to December, 31st 2015. We used an operating record, which includes epidemiological, clinical, biological, therapeutic and evolutionary criteria. During this period, we found that 70 cases were diagnosed and treated in the clinical hematological department of the HMA. We recorded 26 cases of multiple myeloma (37%), 23 cases of leukemia (33%), 19 cases of lymphoma (including 15 cases of non-Hodgkin lymphoma (21.4%) and 4 cases of Hodgkin lymphoma 5.7 %), 1 case of myelodysplastic syndrome (1.4%) and 1 case of polycythemia vera (1.4%). This work allowed us to note a significant increase in malignancies in this study. Hence the importance of raising the awareness of health professionals and raising awareness on a larger scale of the general population to improve the time of care and indirectly improve the prognosis of these diseases.
    VL  - 4
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco

  • Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco

  • Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco

  • Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco

  • Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco

  • Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco

  • Sections